Abstract
Objective
The aim of the study was to evaluate the impact of a drug use evaluation (DUE) program on osteoporosis management in general practice.
Methods
A DUE program, led by pharmacists integrated into two general practice clinics in Melbourne, Australia, was undertaken as part of the Pharmacists in Practice Study. Data on use of anti-osteoporosis medicines and calcium and vitamin D supplements were collected at baseline and 12 months. Following the baseline audit, an intervention comprising prescriber feedback, group education and individual case-conferences with prescribers, and patient education mail-outs was implemented. The primary outcome was the proportion of patients with a diagnosis of osteoporosis and without contraindications to anti-osteoporosis medicines who were prescribed an anti-osteoporosis medicine. Feedback from practice staff and pharmacists was explored qualitatively to evaluate the acceptability of the program.
Results
The proportion of patients without documented contraindications to osteoporosis therapies who were prescribed an anti-osteoporosis medicine increased significantly (134/227 [59.0 %] vs. 168/240 [70.0 %], p = 0.002). The proportion of patients for whom vitamin D and/or calcium supplement use was documented also increased significantly (145/227 [63.9 %] vs. 205/240 [85.4 %], p = 0.002). Practice staff and pharmacists were generally positive about the DUE program.
Conclusions
A practice pharmacist-led DUE program improved the management of osteoporosis in general practice.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.References
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33.
Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.
Kanis JA, Borgstrom F, Zethraeus N, et al. Intervention thresholds for osteoporosis in the UK. Bone. 2005;36(1):22–32.
Bell JS, Blacker N, Edwards S, et al. Osteoporosis—pharmacological prevention and management in older people. Aust Fam Phys. 2012;41(3):110–8.
Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–22.
Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293–305.
Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res. 2004;19(12):1969–75.
Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18(6):805–10.
Bleicher K, Naganathan V, Cumming RG, et al. Prevalence and treatment of osteoporosis in older Australian men: findings from the CHAMP study. Med J Aust. 2010;193(7):387–91.
Papaioannou A, Kennedy CC, Ioannidis G, et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008;19(4):581–7.
Commonwealth Department of Health and Ageing. The national strategy for quality use of medicines. 2002 [cited 22 September 2013]; Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-pdf-execsumbro-cnt.htm.
Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;6:CD000259.
Holloway K, Green T. Drug and therapeutics committees—a practical guide. Geneva: World Health Organization; 2003.
Society of Hospital Pharmacists of Australia Committee of Specialty Practice in Drug Use Evaluation. SHPA standards of practice for drug use evaluation in Australian hospitals. J Pharm Pract and Res. 2004;34(3):220–3.
Dartnell J. Understanding, influencing and evaluating drug use. Melbourne: Therapeutic Guidelines Ltd.; 2001.
Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc. 2004;5(2):98–100.
Bernett GB, Feldman S, Martin H, et al. An opportunity for medication risk reduction, healthcare provider collaboration, and improved patient care: a retrospective analysis of osteoporosis management. J Am Med Dir Assoc. 2003;4(6):329–36.
Laliberte MC, Perreault S, Jouini G, et al. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis. Osteoporos Int. 2011;22(11):2743–68.
Elias MN, Burden AM, Cadarette SM. The impact of pharmacist interventions on osteoporosis management: a systematic review. Osteoporos Int. 2011;22(10):2587–96.
Hall LN, Shrader SP, Ragucci KR. Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic. Ann Pharmacother. 2009;43(11):1781–6.
Tan ECK, Stewart K, Elliott RA, et al. An exploration of the role of pharmacists within general practice clinics: the protocol for the Pharmacists in Practice Study (PIPS). BMC Health Serv Res. 2012;12(1):246.
Ewald D. Osteoporosis—prevention and detection in general practice. Aust Fam Phys. 2012;41(3):104–8.
Australian Institute of Health and Welfare. National health priority areas. 2013 [cited 16 June 2013]; Available from: http://www.aihw.gov.au/national-health-priority-areas/.
The Royal Australian College of General Practitioners. Clinical guideline for prevention and treatment of osteoporosis in postmenopausal women and older men. South Melbourne: RACGP; 2010.
Osteoporosis Australia. Think osteoporosis! (Flow chart for GPs). 2011 [cited 20 June 2013]; Available from: http://www.osteoporosis.org.au/health-professionals/general-practitioners/.
Australian Medicines Handbook. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty. Ltd.; 2013. p. 2013.
Tan ECK, Stewart K, Elliott RA, et al. Stakeholder experiences with general practice pharmacist services: a qualitative study. BMJ Open. 2013;3(9):e003214. doi:10.1136/bmjopen-2013-.
Laliberté MC, Perreault S, Damestoy N, et al. The role of community pharmacists in the prevention and management of osteoporosis and the risk of falls: results of a cross-sectional study and qualitative interviews. Osteoporos Int. 2013;24(6):1803–15.
Henry MJ, Pasco JA, Nicholson GC, et al. Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. Med J Aust. 2011;195(6):321–2.
Otmar R, Reventlow SD, Nicholson GC, et al. General medical practitioners’ knowledge and beliefs about osteoporosis and its investigation and management. Arch Osteoporos. 2012;7(1–2):107–14.
Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
Reid IR, Bolland MJ, Avenell A, et al. Cardiovascular effects of calcium supplementation. Osteoporos Int. 2011;22(6):1649–58.
Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab. 2012;97(8):2670–81.
Ebeling PR, Daly RM, Kerr DA, et al. An evidence-informed strategy to prevent osteoporosis in Australia. Med J Aust. 2013;198(2):90–1.
Acknowledgments
The authors have no potential conflicts of interest that are directly relevant to the content of this study.
We thank the Windermere Foundation for their financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tan, E.C.K., George, J., Stewart, K. et al. Improving Osteoporosis Management in General Practice: A Pharmacist-Led Drug Use Evaluation Program. Drugs Aging 31, 703–709 (2014). https://doi.org/10.1007/s40266-014-0194-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-014-0194-0